A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours.
Yvonne L E AngGwo Fuang HoRoss A SooRaghav SundarSing Huang TanWei Peng YongSamuel G W OwJoline S J LimWan Qin ChongPhyu Pyar SoeBee Choo TaiLingzhi WangBoon Cher GohSoo-Chin LeePublished in: BMC cancer (2020)
The study was registered ( NCT01803503 ) prospectively on clinicaltrials.gov on 4th March 2013.